In this study, we report that Bcl-xL AS oligonucleotides are capable of sensitising colon cancer cells to IR, one of the most commonly used treatment strategies for localised colorectal cancer in an adjuvant setting. Here, BCL2L1 is linked to malignant colon neoplasm.